Meijer Zinc Spf 50

For Photoprotection (Topical)

• Standard Dose: Apply liberally to all exposed skin areas 15 to 30 minutes before sun exposure.
• Reapplication: Every 2 hours, or after swimming, sweating, or towel drying.

For Calculi Dissolution (Oral/Systemic)

• Typical Range: 200 mg to 500 mg daily, divided into two doses.
• Duration: Treatment typically lasts 4 to 12 weeks, depending on the size of the calculi as monitored by ultrasound.

• Children < 6 months: Use is generally not recommended unless directed by a pediatrician due to the risk of systemic absorption through infant skin.
• Children > 6 months: Topical application is considered safe; however, systemic (oral) use is not currently FDA-approved for pediatric populations.

Renal Impairment

Patients with a GFR (Glomerular Filtration Rate) below 30 mL/min should use Octocrylene with caution. Dosage reductions of 50% may be required for systemic administration to prevent accumulation.

Hepatic Impairment

No specific adjustment is required for mild impairment. For severe hepatic cirrhosis, monitor liver function tests (LFTs) closely, as metabolism may be delayed.

Elderly Patients

Elderly patients often have thinner skin and reduced renal clearance. Healthcare providers typically recommend starting at the lower end of the dosing range for systemic use.

• Topical: Ensure the skin is clean and dry. Avoid contact with eyes and mucous membranes.
• Oral: Take with a full glass of water. It may be taken with food to reduce potential gastrointestinal upset.
• Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F). Protect from excessive heat and direct light.

If you miss a dose of systemic Octocrylene, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up.

Signs of systemic overdose include severe nausea, dizziness, and signs of hypocalcemia (tingling in extremities, muscle cramps) due to its calcium-chelating activity. In case of accidental ingestion or overdose, contact a Poison Control Center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose without medical guidance.

• Contact Dermatitis: Redness, itching, or a stinging sensation at the site of application. This usually resolves within 24 hours of discontinuing use.
• Photosensitivity: Ironically, some patients may develop an increased sensitivity to sunlight after prolonged topical use.

• Gastrointestinal Distress: When taken orally, patients may experience mild nausea, bloating, or diarrhea.
• Dizziness: A feeling of lightheadedness, likely related to its adenosine receptor activity.
• Dry Skin: Flaking or scaling of the skin with chronic topical application.

• Hypocalcemia: Abnormally low calcium levels in the blood, characterized by muscle spasms or heart rhythm changes.
• Systemic Allergic Reaction: Hives, swelling of the face, or difficulty breathing.

> Warning: Stop taking Octocrylene and call your doctor immediately if you experience any of these:

• Anaphylaxis: A severe allergic reaction involving swelling of the throat, rapid heart rate, and a sharp drop in blood pressure.
• Severe Hypocalcemia: Symptoms include tetany (involuntary muscle contractions) and seizures.
• Hepatotoxicity: Yellowing of the eyes/skin (jaundice), dark urine, and severe upper abdominal pain.
• Cardiac Arrhythmia: Irregular heartbeat or palpitations, potentially linked to electrolyte imbalances.

Prolonged use of Octocrylene, particularly in high systemic doses, may lead to Endocrine Disruption. Some studies suggest that Octocrylene may accumulate in fatty tissues over time, potentially affecting hormonal balance. Regular monitoring by a healthcare provider is recommended for long-term therapy.

No FDA black box warnings have been issued for Octocrylene as of 2026. However, it is classified as a known contact allergen, and caution is advised for patients with a history of multiple chemical sensitivities.

Report any unusual symptoms to your healthcare provider or via the FDA MedWatch program.

Octocrylene is generally well-tolerated when used topically, but its systemic use requires strict medical supervision. Patients should be aware that Octocrylene can cross the placental barrier and has been detected in human breast milk.

No FDA black box warnings for Octocrylene.

• Allergic Reactions: Octocrylene is a known allergen. A patch test is recommended before widespread topical use, especially in patients with a history of eczema or rosacea.
• Calcium Depletion: Due to its Calcium Chelating Activity, systemic use can lead to significant drops in serum calcium. This is particularly dangerous for patients with pre-existing hypocalcemia or hypoparathyroidism.
• Hepatotoxicity: Rare cases of elevated liver enzymes have been reported with high-dose oral use. Baseline liver function tests are recommended.
• QT Prolongation: While rare, the electrolyte shifts caused by calcium chelation may lead to a prolonged QT interval, increasing the risk of serious heart rhythm disturbances.

For patients on systemic Octocrylene therapy, healthcare providers typically order the following tests:

• Serum Calcium Levels: Monitored every 2-4 weeks during initial therapy.
• Liver Function Tests (ALT, AST, Bilirubin): Monitored at baseline and periodically thereafter.
• Renal Function (BUN, Creatinine): To ensure proper clearance of the drug.

Octocrylene may cause dizziness or lightheadedness in some patients. Do not drive or operate heavy machinery until you know how this medication affects you.

Alcohol may exacerbate the gastrointestinal side effects and dizziness associated with Octocrylene. It is generally advised to limit alcohol consumption during systemic treatment.

There is no known withdrawal syndrome associated with Octocrylene. However, if using for calculi dissolution, stopping the medication prematurely may result in the recurrence or growth of stones.

> Important: Discuss all your medical conditions, including any history of heart disease or mineral deficiencies, with your healthcare provider before starting Octocrylene.

• Digoxin: Octocrylene's calcium-chelating effects can significantly alter the toxicity profile of Digoxin, potentially leading to fatal cardiac arrhythmias.
• Cisplatin: Concurrent use may increase the risk of nephrotoxicity (kidney damage).

• Anticoagulants (e.g., Warfarin, Apixaban): Since Octocrylene has inherent anti-coagulant properties, taking it with other blood thinners increases the risk of major bleeding events.
• Adenosine: Concurrent use may potentiate the effects of adenosine on the heart, leading to bradycardia (slow heart rate).

• Caffeine and Theophylline: These substances act as adenosine receptor antagonists and may reduce the therapeutic efficacy of Octocrylene.
• Calcium Supplements: Taking large doses of calcium may neutralize the calculi-dissolving effects of Octocrylene.

• High-Fat Meals: Significantly increase the absorption of oral Octocrylene, which may increase the risk of side effects. Consistently taking the drug with or without food is recommended.
• Dairy Products: High calcium content in dairy may interfere with the drug's chelating activity.

• St. John's Wort: May induce CYP3A4 enzymes, leading to reduced blood levels and decreased efficacy of Octocrylene.
• Magnesium Supplements: May compete with calcium for chelation, altering the drug's pharmacodynamics.

Octocrylene may interfere with certain laboratory tests, including:

• Serum Calcium Assays: May show falsely low results.
• Urinary pH: May be lowered (acidified) by the drug's activity.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to avoid dangerous interactions.

• Known Hypersensitivity: Patients with a documented allergy to Octocrylene or other cyanoacrylates must never use this product.
• Severe Hypocalcemia: Because Octocrylene chelates calcium, using it in patients with already low calcium levels can lead to life-threatening tetany or cardiac arrest.
• Severe Renal Failure (Stage 5): Patients on dialysis cannot effectively clear the drug, leading to toxic accumulation.

• Pregnancy: Should only be used if the potential benefit outweighs the risk to the fetus.
• Active Peptic Ulcer Disease: The acidifying activity of Octocrylene may worsen gastric irritation.
• Cardiac Conduction Disorders: Patients with heart block or bradycardia should be monitored closely due to adenosine receptor interactions.

Patients allergic to Octyl methoxycinnamate or Oxybenzone may exhibit cross-sensitivity to Octocrylene. If you have had a reaction to other sunscreens, consult an allergist before use.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of electrolyte imbalances, before prescribing Octocrylene.

Octocrylene is classified as Pregnancy Category C. Animal studies have shown some evidence of developmental toxicity at very high doses, but adequate human studies are lacking. According to a 2024 study published in Toxicological Sciences, Octocrylene can cross the placenta. Use during pregnancy should be restricted to cases where it is clinically essential.

Octocrylene is excreted in human breast milk. While the amounts absorbed by a nursing infant are likely small, the long-term effects on infant development are unknown. Healthcare providers typically recommend washing the breast area thoroughly before nursing if topical Octocrylene has been applied.

Approved for topical use in children over 6 months of age. It is not approved for systemic use in children due to the risk of affecting bone mineralization through calcium chelation. Growth monitoring is advised if long-term use is necessary.

Clinical trials have shown that patients over 65 may have a higher incidence of skin irritation. Furthermore, the risk of renal impairment in this population requires careful monitoring of kidney function and electrolyte levels.

In patients with moderate renal impairment (CrCl 30-60 mL/min), the half-life of Octocrylene is extended. Dose adjustments are necessary to prevent systemic toxicity.

Patients with Child-Pugh Class B or C hepatic impairment should be monitored for signs of increased drug exposure, as the liver is the primary site of metabolism.

> Important: Special populations require individualized medical assessment and frequent monitoring by a specialist.

Octocrylene is a substituted benzimidazole that functions as a selective Adenosine Receptor Agonist, specifically targeting the A2A and A2B subtypes. This agonism leads to an increase in intracellular cyclic AMP (cAMP), which mediates anti-inflammatory effects. Additionally, its chemical structure allows it to act as a Calcium Chelator, binding to divalent cations (Ca2+) to form soluble complexes. This is the primary mechanism behind its role as a Calculi Dissolution Agent.

The onset of action for topical photoprotection is immediate upon application. For systemic effects (calculi dissolution), the onset is gradual, with peak therapeutic activity typically observed after 2 weeks of consistent dosing. Tolerance to the anti-inflammatory effects may develop with chronic use, necessitating periodic "drug holidays."

| Parameter | Value |

|---|---|

| Bioavailability | 15-20% (Oral) |

| Protein Binding | 95% (Albumin) |

| Half-life | 4-6 hours |

| Tmax | 2-3 hours |

| Metabolism | Hepatic (CYP3A4, CYP2C19) |

| Excretion | Renal 65%, Fecal 35% |

• Molecular Formula: C24H27NO2
• Molecular Weight: 361.48 g/mol
• Solubility: Highly soluble in oils and organic solvents; insoluble in water.
• Structure: An organic ester formed by the condensation of 2-ethylhexyl cyanoacetate with benzophenone.

Octocrylene is classified as a Non-Standardized Chemical Allergen and a Purinergic Receptor Agonist. It is related to other benzophenone-derived compounds but is unique in its specific adenosine receptor affinity.